Navigation Links
FDA Approves First Ceramic-on-Metal Total Hip Replacement System
Date:6/14/2011

SILVER SPRING, Md., June 14, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration approved on June 13 the first ceramic-on-metal total artificial hip system for patients with osteoarthritis.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

Hip joints consist of bone in the shape of a ball at the top of the thighbone (femur) that fits into a rounded socket in the pelvis (acetabulum).  During total hip replacement surgery, worn and damaged portions of bone and cartilage are removed and replaced with an artificial hip joint.

Specifically, a shell or cup replaces the socket, a stem is inserted into the thighbone and a femoral head or ball at the top of the stem is fitted inside the curved artificial socket where the ball can slide around, allowing for movement.

Previous total hip replacement systems cleared or approved by FDA have used different combinations of metal, ceramic, and polyethylene (a form of plastic). The Pinnacle CoMplete Acetabular Hip System is the first to combine a ceramic ball and a metal socket.

"Orthopedic surgeons and their patients now have an additional option for total hip replacement with the approval of the Pinnacle CoMplete Acetabular Hip System," said Christy Foreman, director of the Office of Device Evaluation in the FDA's Center for Devices and Radiological Health.

The FDA's approval is based on a two-year, randomized clinical trial, which found no clinical difference between 194 patients who received the new ceramic-on-metal system and 196 patients in a control group who received a metal-on-metal hip implant. Two patients who received the Pinnacle CoMplete system required a second surgery to replace their new implant compared with three patients who required a second surgery in the control group.

As a condition of FDA approval, the manufacturer, DePuy Orthopaedics Inc., will conduct a postmarket study, monitoring patients receiving the Pinnacle CoMplete system for adverse events and metal ion concentrations in their blood.

DePuy is located in Warsaw, Ind.

For more information:

Hip Implant Systems
http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/MetalonMetalHipImplants/ucm241594.htm

Media Inquiries: Karen Riley, 301-796-4674, karen.riley@fda.hhs.gov
Consumer Inquiries: 888-INFO-FDA


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... , July 20, 2017  Prime Therapeutics LLC (Prime) ... Gavras , M.D., following today,s Institute for Clinical and Economic ... on the effectiveness and value of abuse-deterrent formulations (ADF) ... the policy roundtable at the meeting. ... a material cost benefit to the use of abuse-deterrent formulations ...
(Date:7/14/2017)... -- It should come as no surprise to anyone that ... midst of a crippling opioid epidemic. According to the ... overdose deaths from opiate-based medications has quadrupled, Says, Dr. ... from 2001 to 2015". During this time, the prescription rate ... drawing a compelling link between prescription and eventual addiction. The ...
(Date:7/12/2017)... 2017  Eli Lilly and Company (NYSE: LLY ... to resolve pending patent litigation in the U.S. District Court ... regarding the Cialis ® (tadalafil) unit dose patent. This ... As part of the agreement, Cialis exclusivity is now expected ... "The unit dose patent for Cialis is valid and ...
Breaking Medicine Technology:
(Date:7/20/2017)... ... July 20, 2017 , ... ... the development of non-invasive devices and systems for monitoring cardiopulmonary diseases, announced today ... will be used to complete regulatory submissions and fund final engineering and initial ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... FDAnews Webinar**, Aug. 9, 2017 — 1:30 p.m. – 3:00 p.m. ET, ... inspections and boosting quality. , It’s known as the “CY2016 Annual FDA Medical ...
(Date:7/20/2017)... , ... July 20, 2017 , ... ... products that further expand its existing adherence automation lines. The ATP® Mini and ... the advanced technology of TCG’s standard products, but at a size and price ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... the Business Architecture Body of Knowledge (BIZBOK® Guide )v 6.0 is now available ... to this effort through Guild collaborative teams. , Non-members may download the ...
(Date:7/20/2017)... VA (PRWEB) , ... July 20, 2017 , ... A ... Social Security cost – of - living - adjustment (COLA) is a bad deal ... The proposed “chained” consumer price index (CPI) would grow even more slowly than the ...
Breaking Medicine News(10 mins):